Company intelligence / Profile preview

Beijing Biote Pharmaceutical Co., Ltd.

Beijing, Beijing, Chinabiotepharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Successfully commercialized Leuprorelin Acetate sterile lyophilized microspheres sustained release for injection, which was the first generic microsphere product marketed in China in 2009

Therapeutic areas: OncologyEndocrinologyWomen's Health
Modalities: Microsphere drug delivery systems
Industry: Biotech

Drug pipeline

1 asset

leuprorelin

Commercial

Indications: Prostate cancer, Breast cancer, Central precocious puberty

Beyond the preview

Go deeper on Beijing Biote Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Biote Pharmaceutical Co., Ltd..

Explore the full profile